Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women

NCT ID: NCT06564883

Last Updated: 2024-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2025-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours. Hyaluronic Acid promotes vaginal moisture, providing symptom relief in various situations such as:

* Vaginismus and other sexual dysfunctions related to penetration
* Users of hormonal contraceptives with lubrication loss
* Postpartum and lactational period
* Post antibacterial or antifungal therapies
* During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy)
* Climacteric (urogenital atrophy)
* Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.)
* Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies
* Post cosmetic and genital rejuvenation therapies

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginismus Vaginal Atrophy Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Arm

Hyaluronic Acid will applied under recommended conditions during the period of T22 ±2 days.

Group Type EXPERIMENTAL

0.20% sodium hyaluronate gel

Intervention Type DEVICE

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.20% sodium hyaluronate gel

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hyaluronic Acid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy research participants, with an active sexual life;
* Intact skin and mucosa in the test region;
* Participants vaccinated for COVID-19 (Corona virus Disease).
* Agreement to adhere to the study procedures and requirements and attend the institute on the day(s) and time(s) determined for the assessments;
* Ability to consent to participate in the study;
* Menopausal participants of any age, without systemic or topical hormone replacement therapy in the last 6 months
* Presenting mild to moderate vaginal dryness (≥0.5 and \<7.5) - according to the Visual Analogic Scale
* Healthy research participants, with an active sex life (at least once a week)

Exclusion Criteria

* Skin pathology in the area of product application;
* Decompensated Diabetes Mellitus (TBD by the institute together with the sponsor);
* Immune insufficiency;
* Current use of the following topical or systemic medications: corticosteroids, immunosuppressants and antihistamines;
* Skin diseases: vitiligo, psoriasis, atopic dermatitis;
* Previous reaction to the category of the product tested;
* Other illnesses or medications that may directly interfere with the study or put the health of the research participant at risk.
* Have used vaginal moisturizing creams and/or intimate lubricants 5 days before the initial study visit;
* Have had sexual intercourse at least 48 hours before the initial study visit;
* Have been diagnosed with a urogenital or vaginal infection in the last 30 days;
* Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last 30 days.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biolab Sanus Farmaceutica

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samuel Guerra Filho, MD

Role: CONTACT

+55 19 37898610

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BS-GIMM24

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Zinc Containing Vaginal Topical " Suppository "
NCT05453227 COMPLETED PHASE1/PHASE2